Is that you? Or is this mom's iPad?
Start adding products to your favorites






Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Studied in Phase 3 clinical trials across escalating dose cohorts — available in 10mg, 20mg, and 30mg vials to support full-scale research protocols from initial titration through advanced study phases.
🧠 Mansplain thisSelect Dose
Lock In Your Protocol
3 vials · Committed
🍪 We use cookies to keep your cart alive and understand how people use the site. No creepy ad tracking — just the basics. Privacy Policy